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Capsule: This expert opinion summarizes current knowledge on risk factors for infertility and
identifies a practical clinical and diagnostic approach for the male and female partners of an
infertile couple aimed to improve the investigation and management of fertility problems.
Background: Infertility represents an important and growing health problem affecting up
to 16% of couples worldwide. In most cases, male, female, or combined factor can be
identified, and different causes or risk factors have been related to this condition.
However, there are no standardized guidelines on the clinical-diagnostic approach of
infertile couples and the recommendations concerning infertility are sometimes lacking,
incomplete, or problematic to apply.
Objective: The aim of this work is to provide an appropriate clinical and diagnostic
pathway for infertile couples designed by a multidisciplinary-team of experts. The rationale
is based on the history and physical examination and then oriented on the basis of initial
investigations. This approach could be applied in order to reduce variation in practice and
to improve the investigation and management of fertility problems.
Methods: Prominent Italian experts of the main specialties committed in the ART
procedures, including gynecologists, andrologists, embryologists, biologists,n.org January 2021 | Volume 11 | Article 5918371
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Frontiers in Endocrinology | www.frontiersigeneticists, oncologists, and microbiologists, called “InfertilItaly group”, used available
evidence to develop this expert position.
Outcomes: Starting from the individuation of the principal risk factors that may influence
the fertility of females and males and both genders, the work group identified most
appropriate procedures using a gradual approach to both partners aimed to obtain a
precise diagnosis and the most effective therapeutic option, reducing invasive and
occasionally redundant procedures.
Conclusions: This expert position provides current knowledge on risk factors and
suggests a diagnostic workflow of infertile couples. By using this step-by-step
approach, health care workers involved in ART, may individuate a practical clinical
management of infertile couples shared by experts.Keywords: infertility diagnosis, female infertility, couple infertility, male infertility, reproduction, diagnosis,
management, assisted reproductive technlogyINTRODUCTION
WHO sets the clinical definition for infertility as a disease of the
reproductive system defined by the failure to achieve a clinical
pregnancy after 12 months or more of regular unprotected sexual
intercourse (1). Although it is difficult to estimate the accurate
global burden of infertility and sub fertility, they affect a
significant proportion of humanity with an estimated
prevalence of 72.4 million infertile people and of these 40.5
million seeking infertility medical care (2). Infertility not only is
related to the reproductive health but has psychological,
economic, and medical implications resulting in trauma, stress,
especially in societies and cultures addressing strong emphasis
on child-bearing (1). As a logical result, and attempting to find a
solution, assisted reproductive technologies (ARTs) spread
globally, constituting a treatment of choice for complicated
fertility disorders (3). The term ART denominates all
interventions, including the in vitro handling of human
oocytes, spermatozoa and embryos, for the purpose of
reproduction (3). Owing to the increasing complexity of
treatment options, ART procedures are delivered via highly
specialized health care workers including: gynecologists,
andrologists, embryologists, geneticists, oncologists, urologists,
psychologists, obstetricians, and others (4). Nevertheless, there
are no international standardized rules and laws regulating these
procedures, resulting in the worldwide spread of ART clinics
having variable quality standards (4). It is estimated that more
than five million infants have been born from ART and,
interestingly, Europe has been the most active continent (5).
In order to reduce variation in practice and improve the way
fertility problems are investigated and managed, different
guidelines have been developed both at national and
international levels.
The National Institute of Health and Care Excellence (NICE)
guidelines make evidence-based recommendations on a wide
range of topics including fertility impairment. They are probably
one of the most important international clinical guidelines
concerning infertility assessment and treatment. Theirn.org 2development follows rigorous methods and criteria to ensure
reliable recommendations for good clinical practice.
The NICE guidelines on fertility examine all aspects related to
fertility, from principles of care and initial advice for people
concerned about delays in conception, to investigation and
management of fertility problems, proper diagnosis work-up
and appropriate treatment approach (https://www.nice.org.uk/
guidance/cg156). However, some conditions related to age of
patients, general health, risk factors, economic situation etc., can
raise critical issues making NICE guidelines difficult to apply.
One issue is linked to the advanced age. According to European
statistical institutes (Eurostat), in 2017 the average age of women
who gave birth to their first child is 31.1 years, the highest in
Europe where the average is 29.1 years. This determines the need
to speed up the diagnostic process of infertile women, who often
come to the observation of reproductive medicine specialists at
an advanced maternal age and with a compromised ovarian
reserve. In addition, some countries do not comply with the
NICE guidelines because they have not the possibility to perform
invasive procedures within their own center or within reasonable
time. Most centers, especially private ones, do not have surgery
rooms capable of performing specific techniques, such as
laparoscopy. Surgical procedures are often performed by
surgeons who are not involved in reproductive medicine, and
who therefore are not familiar with techniques such as ovarian
drilling or conservative tubal surgery, which should be entrusted
to teams with sufficient experience in these procedures. The
aforementioned reasons limit access to the invasive diagnostic
and therapeutic procedures suggested by the NICE guidelines,
which should be reserved for a strictly selected group of patients
in a such different context.
Another issue that limits the use of the NICE guidelines is
linked to the different legislation in force, compared to most
European countries. In Italy, for example, drugs such as
metformin for polycystic ovary syndrome (PCOS) are still off-
label, the cryopreservation of embryos is theoretically prohibited
(although made possible by way of derogation from the law and
with well-defined limits) and the donation of gametes is stillJanuary 2021 | Volume 11 | Article 591837
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economic fee.
The NICE guidelines also deal with male factor infertility and
its medical and surgical management. On this topic, there is a
great difference with the detailed analysis of female factor
infertility. For instance, some important risk factors for male
infertility are not mentioned (e.g. cryptorchidism, orchitis and
epididymitis, testicular hypotrophy, seminal tract infections,
testicular trauma or torsion, testicular neoplasia, systemic
diseases, hormonal derangement due to anabolic steroid use,
etc.). Moreover, minimal diagnostic work-up is not defined,
other than seminal analysis. Recommendations about physical
examination, hormonal tests, microbiological analysis, and
imaging diagnostics are lacking.
The present expert opinion, describes a practical clinical and
diagnostic pathway for infertile couples designed by a
multidisciplinary team of experts in the ART procedures,
named “InfertilItaly group” , including gynecologists,
andrologists, embryologists, biologists, geneticists oncologists,
and microbiologists. The objective of this work is to provide
clear indications for the management of the infertile couple,
completing the diagnostic process as accurately and quickly as
possible, taking into account the Italian health, legislative, and
social context.METHODS
At the beginning of 2020, a final meeting of Italian experts in
couple infertility was held in Rome to discuss risk factors and
diagnostic workflow of infertile couples. This document is the
result of several meetings, drafts, data discussions, and covered
guidance for the care of infertile couples. The proceedings
journal is published in Italian (6) and it is downloadable at
https://www.ccgm.it website. The final meeting in February 2020
was organized to provide a forum for interdisciplinary discussion
involving as many interested parties as possible. More than 100
participants from all Italian Regions took part in the meeting.
They included all the professionals involved in the management
of the infertile couple. The objectives of the meeting were a) to
review literature about causes and risk factors of infertility, b) to
identify unresolved issues in the field, and c) to provide standard
recommendations tailored for couples seeking fertility in the
Italian context.
To permit in-depth analysis and discussion, the meeting did
not cover the whole field of ART. Instead, it focused on a selected
number of topics including infertility risk factors, national and
international surveillance of ART, diagnostic tools and
procedures, psychosocial issues, ethical and law aspects in
relation to the individual, to the couple and to the offspring, as
well as issues of equitable access, the role of consumers.
Background papers were commissioned from invited
speakers and peer-reviewed prior to the meeting. The papers
were briefly presented with emphasis being given to discussion
and the delineation of recommendations for practice and future
research. All of the meeting sessions were plenary to allow full
interaction among the different disciplines. A wide variety ofFrontiers in Endocrinology | www.frontiersin.org 3views and approaches was presented in an intense, dynamic, and
rich debate.
This document comprises five sections, consisting of the main
specific areas discussed and the recommendations agreed to by
the meeting participants: i) risk factors, ii) assessment of infertile
couples, iii) infertile couple pathway, iv) gynecological specific
flow charts, and v) andrological specific flow charts. The sections
are grouped by expertise area in an order similar to that of the
final meeting program but also in a way that the different views
are juxtaposed or complementary. Despite the diverse opinions
on ART voiced at the meeting, there were many points upon
which a final consensus was reached.
Risk Factors
Despite general perception that causes of infertility predominantly
affect female, the causes of infertility are in fact equally distributed
between the sexes. Indeed, according to the American Society for
Reproductive Medicine, in 40% of couples with infertility, the female
partner is either the single or a contributing cause of infertility, in
40% it is the male partner and in the remaining 20% there are no
identifiable reasons termed unexplained infertility (7). Male factor
infertility is defined as one ormore abnormal parameters detected on
semen analysis or the presence of inadequate sexual or ejaculatory
function (8). The main fertility risk factors affecting males, females
and both sexes are listed in Table 1.
Risk Factors for Both Sexes
Several common factors may affect fertility in both sexes with
different impact (9). It is well known that fertility declines with
age in males and females, but the decline is much faster in
women. Female age is not a modifiable risk factor, this is linked
both to the progressive depletion of the number of oocytes
contained within the ovary (ovarian reserve), and to the
progressive deterioration of their chromosomal and structuralTABLE 1 | Female and male infertility risk factors.
Both genders Female Male
Family history of
infertility
Age >35 years Cryptorchidism
Recurrent abortions Reduced ovarian reserve
(AMH and/or AFC count)
Testicular hypotrophy
Obesity Ovulation Disorders Testicular cancer
Using of anabolic
steroids
Infertility >3 years Known genetic factors






Family history of POF Testicular torsion






Cystic fibrosis Testicular microlithiasis
Infection Unhealthy diet and obesity
Pollution
Cigarette smokingJanuary 2021 | VAFC, antral follicle count; AMH, anti-müllerian hormone; BMI, body max index; PID, pelvic
inflammatory disease; POF, primary ovarian insufficiency.olume 11 | Article 591837
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begin to desire a pregnancy has progressively increased the time
window in which numerous lifestyle factors can exert their
negative influence on the reproductive system, gametes, and
general health. These lifestyle risk factors include: not
achieving dietary recommendations and excessive physical
activity participation (11–13); overweight (both BMI >25 and
BMI >30 are related to a reduction in fertility) (14–17); physical,
social or psychological stress (18–20); smoking tobacco (21–23);
alcohol consumption; a high caffeine consumption; taking illicit
drugs (24, 25); and a wrong timing of sexual intercourse at
reproductive aim (26).
Growing evidence exists regarding the role of infectious
agents on fertility impairment. In women, they can cause
pelvic inflammatory disease and tubal obstruction (27) and in
men they can lead to organ damage, create an obstruction or
induce cell damage via mediators of inflammation or binding to
spermatozoa (28). Interestingly, from 1993WHO established the
role of genital tract infections in human infertility and further
studies reported that 15%–20% of infertile subjects are affected
by semen infection (29).
Female Risk Factors
Female infertility may have different causes, like alterations of the
reproductive system, congenital malformations, infections and
hormonal dysfunctions. Particular attention should be paid to
women with reduced ovarian reserve, linked to iatrogenic causes
(for example previous cytotoxic treatments), or linked to a
reduced follicular heritage from birth (POF family history)
(10). In addition to a reduced ovarian reserve, several risk
factors can affect the female fertility, and the main ones are
summarized in Table 1. Alongside lifestyle risk factors, an
important determinant of female infertility is linked to the
reduction in the number of ovulatory and, therefore,
potentially fertile cycles. PCOS is the most common endocrine
disorder and is the leading cause of anovulatory infertility in
women. It is found in 5%–10% of the female population of
reproductive age (30). According to ESHRE guidelines, PCOS
has to be investigated in cases of clinical or biochemical
hyperandrogenism, ovulatory dysfunction, or polycystic ovaries
(31). While ESHRE guidelines suggest that where irregular
menstrual cycles and hyperandrogenism are present ultrasound
is not necessary for diagnosis, in infertile couples it should be
mandatory in order to exclude other possible causes of
female infertility.
Together with PCOS, all causes of amenorrhea may be a risk
factor for female infertility since they are associated with
ovulatory disorders. The term amenorrhea defines the absence
of spontaneous menstruation for a period of at least 90 days or,
according to some classifications, at least 180 days. It is necessary
to differentiate physiological amenorrhea (present in some
phases of a woman’s life, such as pre-pubertal age, pregnancy,
and post-menopause) from pathological amenorrhea. The
prevalence of the latter is around 3%–4%. Among the various
classifications, the distinction between primary amenorrhea
(absence of menarche from the age of 15 in the presence of
secondary sexual characteristics or, in the absence of the latter,Frontiers in Endocrinology | www.frontiersin.org 4the absence of menarche from the age of 13) and secondary
(absence of menstrual cycles for a period of at least 6 months in a
woman who has had previous regular menstrual cycles or at least
12 months in a woman with oligomenorrheic cycles) is considered
particularly useful. Indeed, in the presence of secondary
amenorrhea, there is a previous evidence of anatomical activity
functional of the reproductive axis and of the internal and external
genital apparatus, which on the contrary is to be proved in the case
of primary amenorrhea. For a list of possible causes of amenorrhea,
see the position statement of theAmerican Society forReproductive
Medicine (32).
Endometriosis is another known factor of female infertility.
Epidemiological data available in the literature, estimate that 6%–
10% of the general female population suffers from endometriosis. In
infertile women, the prevalence is estimated to be between 25% and
30% while 30%–50% of patients with endometriosis, independently
from its stage, are infertile. Hughes et al. reported a monthly fertility
rate for patients with endometriosis between 2% and 10%,
considerably lower than that of the general population estimated
to be between 15% and 20% (33).
Together with the above, other risk factors have been
associated with female infertility, although their prevalence is
lower than the previous ones.
Male Risk Factors
Male infertility is usually related to a reduced number of
spermatozoa or to abnormalities in their quality. Two main
conditions of male infertility are recognized: primary infertility,
defined when the man has never induced a pregnancy and
secondary infertility, when the man has previously fathered.
An important risk factor is cryptorchidism. In fact, in
congenital cryptorchid testes germ cell loss and the
deterioration of the testicular structure can be observed.
Importantly, these detrimental changes are observed to a
higher level when testes remain undescended (34). Although
orchiopexy corrects the inappropriate temperature exposure of
the testis, surgery may not reverse the dysgenetic damage that
underlies cryptorchidism in the first place (34). Another debated
but recognized risk factor is varicocele that, on one side is
associated with negative effects on semen quality, sperm
function, testicular histology, and reproductive hormones and,
on the other side it is present in men able to father children (35).
Besides, patients with testicular cancer may have infertility both
before cancer treatments due to systemic effects, endocrine
changes, possible autoimmune effects, intrinsic testicular
damage, possible congenital abnormalities in testicular
maturation and after gonadotoxic effects related to
orchiectomy, radiation, and chemotherapy (36). Growing
evidence is also focusing on genetic factors and it is indeed
well established that genetic causes account for 10%–15% of
infertility cases, including chromosomal abnormalities and
single-gene mutations (37). In addition to these well-known
factors, growing evidence suggests that obesity, unhealthy diet,
cigarette smoking and pollution may seriously affect sperm
parameters and reduce male fertility (38–41). Again, besides
bacterial semen infections, the presence of HPV on the male
partner is now considered a risk factor both for natural andJanuary 2021 | Volume 11 | Article 591837
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when infection is present on sperm there is a negative effect on
the ongoing pregnancy rate and live birth rate as well as an
increase in the rate of miscarriage (44). Finally, anti-sperm
antibodies (ASA) have been shown to reduce sperm motility,
natural fertilization, and conception thus inducing couple
fertility (45). They are frequently associated with semen
infections and recently it has been demonstrated that ASA-
positive men had lower rates of pregnancy and live births
following IVF (46). Therefore, their presence should be
considered in infertile couples. Finally, many other factors with
more limited evidence are included, such as testicular torsion
and microlithiasis.
Assessment of Infertile Couples
The pathway to pregnancy in infertile couples is usually long
and requires a high level of resilience owing to several
factors including medical procedures, economic costs and
psychological stress. In order to minimize the impact and toFrontiers in Endocrinology | www.frontiersin.org 5maximize the results, a well-integrated and multidisciplinary
approach including all the different specialists of reproduction
is necessary. In fact, it is mandatory to identify the most
appropriate procedure with a gradual approach to both
partners to obtain a precise diagnosis and the most effective
therapeutic option, reducing invasive procedures that are
not necessary.
For this reason, the first step should be a preliminary
evaluation of both the male and female partner, drawing up
the medical history and performing a clinical examination,
taking into account the main issues listed in Tables 2 and 3
for male and female respectively. In addition to the medical
history and clinical examination, semen analysis, endocrine
assessment, and ultrasound scanning should be performed in
order to have a more comprehensive picture.
Infertile Couple Pathway
Health workers dealing with infertility should be able to guide
couples through a clear, standardized and operative flow,TABLE 2 | First gynecological approach.






































EndometriosisJanuaryBMI, Body mass index; IUD, intrauterine contraceptive device; PCO, Polycystic ovary; PID, pelvic inflammatory disease; VIP, voluntary interruption of pregnancy.TABLE 3 | First andrological approach.
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output of the diagnostic and treatment pathway. In Figure 1, we
reported the results of an Italian consensus recommending a
comprehensive approach to infertile couples. Based on WHO
definition, couples should firstly be divided based on the time of
offspring search (< or >12 months). The threshold chosen for the
duration of pregnancy seeking is crucial and can impact on the
prevalence of the disease, avoiding couples to undergo
unnecessary diagnostic tests or to the risk of overdiagnosis
(47). The WHO recommends preconception care between 3
and 6 months before trying for a baby because of its positive
impact on maternal and child health outcomes (https://apps.
who.int/iris/handle/10665/78067). As medical history, physical
examination and ultrasound for women are part of routine pre-
conception counselling, the gynecologic and whole health
evaluation of the woman seeking pregnancy can be started
independently of the diagnosis of infertility (http://www.undp.
org/content/undp/en/home/librarypage/mdg/the-millennium-
development-goals-report-2015.html). Possible factors involved
in determining female infertility can be investigated as early as
this stage (Table 2). For males, medical history, physical
examination, sperm analysis, and ultrasound should be
performed as shown in Table 3 (48).
If no alteration or risk factors are highlighted by this first level
examination, couples are recommended to have free intercourse
waiting till 12 months. If any alteration or risk factor emerges,
the affected partner should undergo further analyses as
described below.
Couples with more than 12 months infertility, should
undergo the same preliminary approach. If no alteration is
highlighted in both partners, expectant management isFrontiers in Endocrinology | www.frontiersin.org 6acceptable. Indeed, no significant differences in live birth rates
between expectant management and other interventions for
unexplained infertility have been recently reported, at least
excluding patients at poor prognosis of natural conception
(49). However, alongside a waiting strategy, further diagnostic
investigations are advisable: males should perform a
comprehensive microbiological screening (see Andrological
Specific Flow-Charts). If any infection is detected, it should be
treated and checked after the end of treatment. On the other
hand, if any alteration or risk factor emerges from the
preliminary examination, the affected partner should undergo
further analyses. In particular, targeted examination should be
performed for women based on specific risk factors as alterations
observed at trans-vaginal ultrasound (Figure 2) or clinical
conditions (Figures 3–5 explained below). For men,
microbiology tests (Figure 6) or targeted flow charts (Figures
7–9 explained below) should be followed based on
sperm parameters.Gynecological Specific Flow Charts
Second Level Diagnostic Investigation
In a couple with > 12 months infertility, where the male partner
has normal sperm parameters and woman has no known risk
factors, second level investigations should start with the antral
follicle count (AFC) and anti-mullerian hormone (AMH)
dosage. If the woman was diagnosed as “poor responder”, the
couple should be recommended to undergo in-vitro fertilization
(IVF) independent of age (Figure 3). As the number and the
quality of oocytes are directly related to the probability of
obtaining a live birth through IVF, a waiting policy in theseFIGURE 1 | Infertile couple flow chart.January 2021 | Volume 11 | Article 591837
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conception was not obtained (50, 51). Indeed, the age-related
decline in ovarian reserve has been shown greater in infertility
patients than fertile women (52).Frontiers in Endocrinology | www.frontiersin.org 9Likewise, women older than 40 years old should be directed to
IVF independently from the ovarian reserve because in older
women with no other risk factors the immediate access to IVF
demonstrated superior pregnancy rates compared to other ARTFIGURE 6 | Andrological specific flow chart: microbiological assessment in male with anomalies found in infertility counseling.FIGURE 7 | Andrological specific flow chart: diagnostic investigation for man with azoospermia, cryptozoospermia, and severe oligozoospermia (<5 total million).January 2021 | Volume 11 | Article 591837
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physiology cannot be accurately investigated by means of the
ordinary diagnostic work up. Thus, in women older than 40
years, unexplained infertility cannot be diagnosed easily and
women encountering a physiological “age-related infertility”
could be treated without a true indication (54). Although an
immediate IVF strategy in these couples has theoretical
advantages, there is no strong evidence in support of treatment
versus a waiting policy (55).
If AFC and AMH are normal (i.e. patients cannot be defined as
poor responders) further steps depend on the time of infertility (<
or >2 years) and on female age. If the time of infertility is < 2 years,
the management depends on the age: in women with less than 35
years (Figure 4), an hysterosalpingosonography (HSSG) should beFrontiers in Endocrinology | www.frontiersin.org 10performed. In case of tubal patency, it can be suggested intra-
uterine injection (IUI) as first approach, as the chance of achieving
a live birth are higher than expectant management (56). VF should
be recommended after 3 IUI attempts (57), as the same chance to
have a pregnancy by IVF (about 30% per attempt) are achieve at
the seventh cycle of IUI (58). We do not consider all these
attempts acceptable, as time to pregnancy and the couples’
compliance could be compromised after such numbers of
failures. Furthermore, previous evidence suggests that the
number of IUI attempts should be limited up to four (59–61).
If the HSSG highlights no tubal patency, a diagnostic and/or
operative laparoscopy could be proposed, as laparoscopy in
women with unexplained infertility may reveal previously
undiagnosed pathologies that could require ART, and in thoseFIGURE 8 | Andrological specific flow chart: diagnostic investigation for man with moderate oligozoospermia (5–39 total million).FIGURE 9 | Andrological specific flow chart: diagnostic investigation for man with asthenozoospermia.January 2021 | Volume 11 | Article 591837
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pregnancy rate (62). If laparoscopy show tubal patency or it is
possible to perform an operative laparoscopy, 6 months of free
intercourses or IUI, can be suggested. If laparoscopy confirms
tubal occlusions, the couple should be directed to IVF.
If a female age is between 35–40 years (Figure 5) HSSG could
be performed. In case of tubal patency, IUI can be suggested as
first approach. IVF should be recommended after 3 IUI attempts.
If the HSSG highlights no tubal patency, IVF should be
recommended. Independently from the ovarian reserve, in
presence of hydrosalpinxes (often related to a PID history) a
diagnostic and operative laparoscopy should be proposed before
IVF (63–66). In case of dysmenorrhea/dyspareunia or others
signs suggesting for mild endometriosis or IVF refusal (67, 68), a
diagnostic laparoscopy within 3 months could be proposed,
because undiagnosed or subtle pelvic abnormalities may be a
significant cause of IVF failure (69).
If the time of infertility is >2 years and women age is <40
years, IVF should be proposed. Laparoscopy must be limited to
few selected cases (IVF refusal, history of PID/hydrosalpinxes,
dysmenorrhea/dyspareunia) after a careful risk benefit
assessment. Male partner of couples candidate to IVF could be
tested for sperm aneuploidy and nuclear integrity tests.Andrological Specific Flow Charts
Microbiological Assessment
The WHO guidelines for the management of male infertility
include microbiological investigation and the diagnostic
examinations of male accessory gland infection (MAGI) (70).
MAGI comprise orchitis, epididymitis, vesiculitis, prostatitis, and
urethritis, which are potentially reversible causes of male
infertility (71). Following the WHO’s recommendations (70),
medical history, physical examination and sperm analysis play a
crucial role to suggest a microbiological assessment to the male
partner of an infertile couple. In particular, leukocytospermia
(leukocytes >1 million/ml), more frequently occurring in infertile
patients compared to fertile men (72), deserves microbiological
investigation, as suggested by the American Society for
Reproductive Medicine (ASRM) Practice Committee (73).
There is a lack of consensus about the specific microbiological
analysis that should be requested in infertile patients with MAGI.
Although the WHO guidelines (70) indicate sperm culture, more
recent research suggests that the urethral swab, which could
more accurately detect intracellular microorganisms such as
mycoplasmas (71, 74), may be useful. Accordingly, a
systematic review with meta-analysis carried out on cohort and
case-control studies found an association between Mycoplasma
hominis and Ureaplasma urealyticum and male infertility,
underlining the importance of their identification (75). If the
culture is negative, the specialist could decide, case by case, both
to treat the male with anti-inflammatory or to request second
level tests. In the case of positive culture, the female partner
should also be tested and tailored treatment should be prescribed
to patients with infection. A microbiological re-evaluation at theFrontiers in Endocrinology | www.frontiersin.org 11end of the treatment may be useful because of the relatively high
persistence rate at the end of the antibiotic treatment (71).
The microbiological assessment of infertile couples should
include the search for Papillomavirus (HPV) DNA, especially in
case of current or anamnestic presence of condylomatosis, or in
recurrent pregnancy loss. Accordingly, HPV infection shows a
significantly higher prevalence in infertile patients compared to
fertile men (20.4% vs. 11.4%), as indicated by a meta-analysis
(76). Also, results from 5203 men revealed significantly worse
conventional sperm parameters in HPV-positive than HPV-
negative patients, with the motility being the parameter more
strongly associated with HPV-infection. Importantly, a
significantly higher miscarriage rate has been reported in
HPV-positive patients compared to controls (77). Finally, if the
HPV DNA test is positive, both male and female should be
counseled for possible HPV vaccination and followed-up at 3
and 6 months after counseling.Azoospermia, Cryptozoospermia, and Severe
Oligozoospermia (< 5 Total Million)
The first step for men with azoospermia, cryptozoospermia and
severe oligozoospermia (<5 total million sperm), should be the
assessment of testicular volume and sex hormones levels (48, 73, 78).
If both, testicular volume and FSH, LH, and total testosterone
(T) are normal, further analyses are performed based on semen
volume: on one hand, if it is reduced or absent, a trans-rectal
ultrasound (TRUS) and the search of sperm in the urine sample
should be performed to evaluate the possibility of retrograde
ejaculation (79–82) or vas deferens obstruction. In the latter case,
the CFTR gene mutations should be investigated (83). On the
other hand, if the semen volume is normal, TRUS could highlight
genital tract obstruction and vas deferens pathologies and should
be investigated as above described (84). At the same time scrotal
ultrasound should exclude epididymal abnormalities (85, 86). If
no alteration is found, histological/cytological evaluation may be
performed to highlight spermatogenic function, distinguishing
obstructive forms from primary testiculopathy (87, 88). In case of
spermatogenic impairment, it makes sense to perform genetic
screening for karyotype and Y microdeletions (89–91).
If the testicular volume is normal or reduced, hormonal levels
lead to further investigation: in case of increased FSH and
normal LH and testosterone levels, genetic screening for
karyotype and Y microdeletions should be performed (92) and
histological/cytological evaluation procedure could be performed
aimed to clarify the tubular status. When LH is increased,
testosterone normal or increased and FSH normal or reduced,
the genetic screening for androgen receptor (AR) mutations
should be performed (93) and also in this case, histological/
cytological evaluation option may be considered.
Lastly, if the testicular volume is reduced, FSH and LH and
testosterone are normal or reduced, pituitary-testicular axis
should be assessed by both, hormonal tests for hypopituitarism
and pituitary imaging to assess the abnormalities (94). In
addition, if pituitary imaging doesn’t reveal any alteration,January 2021 | Volume 11 | Article 591837
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mutations should be performed (95–97).
Moderate Oligozoospermia (5–39 Total Million)
Also for men with moderate oligozoospermia (from 5 to 39 total
million sperm), the first approach should be the assessment of
testicular volume and hormonal asset (48, 73, 78).
If both, volume and hormones are normal, testicular doppler
ultrasound should be performed aimed to exclude the presence
of varicocele (98–100). Also based on semen volume, pH, and
TRUS, four conditions should be considered: MAGI (see the
section Microbiological Assessment—Figure 6), partial genital
tract obstruction (101), retrograde ejaculation, and idiopathic
oligozoospermia (102).
In the last scenario, a genetic screening for karyotype should
be performed (92) and, in case of sperm count below 10 million,
histological/cytological evaluation, could highlight the cause of
oligozoospermia (88, 103).
In presence of normal or reduced testicular volume, normal
or increased FSH and LH and normal T and PRL, the presence of
varicocele or idiopathic infertility should be investigated as
described above (99, 100).
Finally, if testicular volume, FSH, LH and T are normal or
reduced and PRL is normal or increased, pituitary-testicular axis
should be assessed by both, imaging and further hormonal test
for hypopituitarism as previously described (94) (see Figure 7).
Asthenozoospermia
In presence of isolate asthenozoospermia, first of all genital tract
infections should be excluded (see the section Microbiological
Assessment—Figure 6) and a further semen analysis should be
performed after 3 months from the end of treatment to re-
evaluate such condition. If confirmed, a scrotal doppler-
ultrasound, a TRUS and test for anti-sperm antibodies (ASA)
test should be performed (104). Based on the results, we could
face three scenarios: i) immunological infertility (105); ii)
testicular or post-testicular infertility, including epididymal-
deferential alterations, prostate chronic abnormalities or
varicocele (106, 107) and iii) idiopathic infertility. In the case
of idiopathic infertility, mutation of dynein gene should be
investigated (108, 109). In case of presence of possible
environmental or lifestyle causes of semen alteration,
asthenozoospermia should be confirmed after 3 months from
removal of risk factors (frequent saunas, smoking, work
activities, tight sportswear) (108, 110, 111).CONCLUSIONS
This expert opinion is an attempt to create a comprehensive,
clear, standardized and personalized approach to infertile
couples considering their health and wellness of offspring
conceived. It contains practical recommendations useful for
health workers dealing with reproductive health and to the
research community. Considering the dynamism and the
continuous evolution in the setup of diagnostic tools, this
expert opinion provides just a general informed debateFrontiers in Endocrinology | www.frontiersin.org 12intending to stimulate further discussions among all those
interested in the scientific, social, and ethical aspects of ART
and to provide some guidance and clarification for
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